Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?

This publication has 11 references indexed in Scilit:

• Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients – interaction with ACE insertion/deletion polymorphism
  Kidney International, 2006
• Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects
  Diabetologia, 2005
• Preventing end stage renal disease in diabetic patients — genetic aspect (part I)
  Journal of the Renin-Angiotensin-Aldosterone System, 2005
• Progression of nephropathy in type 2 diabetic patients
  Kidney International, 2004
• Genetic Variation in the Renin-Angiotensin System and Progression of Diabetic Nephropathy
  Journal of the American Society of Nephrology, 2003
• Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy
  Diabetes Care, 2003
• Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
  New England Journal of Medicine, 2003
• Chronic Proteinuric Nephropathies. II. Outcomes and Response to Treatment in a Prospective Cohort of 352 Patients
  Journal of the American Society of Nephrology, 2000
• Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.
  Diabetes, 1998
• Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study
  BMJ, 1996